期刊文献+

2008-2012年我院严重药品不良反应报告分析 被引量:11

Clinical Analysis of Serious Adverse Drug Reactions in Peking Union Medical College Hospital in 2008-2012
下载PDF
导出
摘要 目的:分析我院严重药品不良反应(ADR)的药品、发生机制、高危因素、防治措施,为临床安全用药提供参考。方法:收集2008年1月-2012年12月我院上报北京市药品不良反应监测中心的药品不良反应,根据《常见严重药品不良反应技术规范及评价标准》确定严重药品不良反应,并对怀疑药品、ADR类型、发生时间、住院费用及转归进行回顾性分析。结果:2008年1月-2012年12月上报的药品不良反应共545例,其中42例为严重不良反应,包括过敏性休克、再生障碍性贫血、粒细胞缺乏症、血小板减少症、全血细胞减少症、急性肝衰竭、急性胰腺炎、急性肾衰竭、中毒性表皮坏死松解症等。引起严重ADR前3位的药品分别是对比剂、抗菌药物和抗肿瘤药物。涉及男22例,女20例,平均年龄46岁,住院时间平均41 d,住院费用平均273 015.39元,住院药物费用平均80 135.69元。5例既往有食物或药物过敏史,3例死亡,39例患者停药或对症治疗后均好转出院。结论:医院应不定期开展医疗安全案例警示培训,重点关注药品不良反应,尤其是新的和严重的不良反应。 Objective:To analyze the mechanisms,risk factors and preventions of serious adverse drug reactions(ADRs) in Peking Union Medical College Hospital(PUMCH) in order to provide the basis for safe drug use in clinical practice. Methods:The ADRs were collected from doctors,pharmacists and nurses from January 2008 to December 2012 in PUMCH. The serious ADRs were diagnosed according to the clinical manifestations and the"Serious Adverse Drug Reaction Technology Standards and Evaluation Criterion"of Ministry of Public Health in China. The type and time of ADR,drugs associated with adverse reactions,duration of hospitalization,cost of hospitalization and outcome of patients were retrospectively analyzed. Results: A total of 545 ADRs were reported in the period between January 2008 and December 2012 in PUMCH. According to the evaluation criterion,42 reports were determined as serious ADRs. They comprised 22 males and20 females with an average age of 46 years,an average duration of hospitalization of 41 days,and an average cost of273 015. 39 yuan. Five patients had their drug or food allergic history. The type of serious ADRs included anaphylactic shock,aplastic anemia,agranulocytosis,thrombocytopenia,pancytopenia,acute liver failure,acute pancreatitis,acute renal failure and toxic epidermal necrolysis. Thirty-nine patients improved and were discharged after drug withdrawal and symptomatic treatment,and three patients died. The top three drugs caused serious ADRs were contrast agent,antineoplastic drug and antibiotics. Conclusion:The hospital needs to have medical alart training regularly,and establishs the rescue proscess and emergency measures. The clinicians and pharmacists need to closely moniter the signs and symptoms of adverse reactions especially new and serious ADRs.
出处 《药物流行病学杂志》 CAS 2014年第8期486-491,共6页 Chinese Journal of Pharmacoepidemiology
关键词 严重药品不良反应 报告 监测 药物警戒 Serious adverse drug reactions Report Monitoring Pharmacovigilance
  • 相关文献

参考文献21

  • 1Waller P. Pharmacoepidemiology-a tool for public health [ J ]. Pharmacoepidemiol Drug Saf, 2001,10 ( 2 ) : 165-172.
  • 2国家药品不良反应监测中心.常见严重药品不良反应技术规范及评价标准[EB/OL].http://wenku.baidu.corn/view/806c64e9856a561252d36f49.html.
  • 3周细平,李宏.碘造影剂所致速发型过敏反应[J].药物不良反应杂志,2011,13(1):21-26. 被引量:30
  • 4Idee JM, Pines E, Prigent P, et al. Allergy-like reactions to i- odinated contrast agents. A critical analysis [ J ]. Fun-dam Clin Pharmaco1,2005,19 (3) :263-281.
  • 5Brockow K, Christiansen C, Kanny G, et al. Manage-ment of hypersensitivity reactions to iodinated contrast media[J]. Allergy,2005,60(2) :150-158.
  • 6Trainer MR, yon Elm E, Loubeyre P, et al. Pharmaco- logical prevention of serious anaphylactic reactions due to iodinated contrast media: systematic review [ J ]. BMJ, 2006, 333 (7570) :675.
  • 7Liceardi G, Lobefalo G, Di Florio E, et al. Strategies for the prevention of asthmatic, anapbylactie and anaphylactoid re- actions during the administration of anesthetics and/or con- trast media[ J]. J investig Allergol Clin Immunol, 2008.18 (1) :1-11.
  • 8Gruchalla RS, Pirmohamed M. Clinical practice. Antibiotic allergy [ J]. New Engl J Med, 2006,354(6):601-609.
  • 9Needle MN. Safety experience with IMC-225, an antiepi- dermalgrowth factor recepter antibody [ J]. SeminOncol, 2002,29(Suppl 14) :55-60.
  • 10Saltz LB, Meropol N J, Loehree PJSR, et al. Phase lItrail of cetuximab in patients with refractory colorectal cancer expre- ssthe epidermal growth factor recepter [ J ]. J ClinOncol, 2004,22(7) :1201.

二级参考文献72

  • 1郑田芝.胃肠病学[M].3版.北京:人民卫生出版社.2000:308.
  • 2Meier Y, Cavallaro M, Roos M, et al. Incidence of druginduced liver injury in medical inpatients [ J ]. Eur J Clin Pharmacol, 2005, 61 (2) : 135-143.
  • 3A proposal of diagnostic criteria of drug-induced liver injury [ C ]//: Proceeding of the Third Drug and Liver Meeting. Tokyo: Toryo Printing Co., Ltd, 1978:96-98. (in Japanese).
  • 4Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting[ J]. Int J Clin Pharmacol Ther Toxicol, 1990, 28 (8): 317- 322.
  • 5Danan G, Benichou C. Causality assessment of adverse reactions to drngs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries [ J ]. J Clin Epidemiol, 1993,46 ( 11 ) : 1323-1330.
  • 6Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis [J]. Hepatology, 1997, 26(3) :664-669.
  • 7Iwasa M, Zeniya M, Kumagi T, et al. Modified diagnostic criteria of drug-induced liver injury proposed by the international consensus meeting [ J ]. Hepatogastroenterology, 2005, 52(63):869-874.
  • 8Lucena MI, Camargo R, Andrade R J, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity[ J ]. Hepatology, 2001,33 ( 1 ) :123-130.
  • 9Fontana RJ, Watkins PB, Bonkovsky HL, et al. DrugInduced Liver Injury Network (DILIN) prospective study: rationale, design and conduct [J]. Drug Saf, 2009,32 ( 1 ) :55-68.
  • 10Fontana ILl, Seeff LB, Andrade R J, et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop [ J ]. Hepatology, 2010,52 ( 2 ) :730 -742.

共引文献95

同被引文献74

  • 1束庆,朱怀军,刘蕴星,葛卫红.硫唑嘌呤代谢酶基因多态性与其导致的不良反应的相关性研究进展[J].中国医院药学杂志,2020,40(3):349-355. 被引量:5
  • 2陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 3陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:32-33.
  • 4卫生部,国家中医药管理局,总后卫生部.抗菌药物临床应用指导原则[S].卫医发[2004]285号,2004:11.
  • 5卫生部,国家中医药管理局,总后勤部卫生部.医疗机构药事管理规定[S].卫医政发[2011]11号,2011.
  • 6药品不良反应报告和监测管理办法[S].中华人民共和国卫生部令第81号,2011.
  • 7卫生部.药品不良反应报告和监测管理办法[S].卫生部令第81号,2011,5,4.
  • 8国家食品药品管理总局.国家药品不良反应监测年度报告(2013年)[EB/OL].http://unow.sda.gov.cn/WS01/CL0078/99794.htm,2014-05-14/2014-12-05.
  • 9国家食品药品监督管理总局药品评价中心.药品不良反应信息通报第21期警惕注射用头孢哌酮钠舒巴坦钠、清开灵注射剂的严重不良反应[EB/OL].http://www.cdr.gov.cn/xxtb-255/ypblfyxxtb/200904/t20090422-2838.html,2009-04-20/2015-04-03.
  • 10国家食品药品监督管理总局药品评价中心.药品不良反应信息通报第14期警惕头孢曲松钠的严重过敏反应、头孢曲松钠临床使用中应注意的问题[EB/OL].http:∥www.cdr.gov.cn/xxtb-255/ypblfyxxtb/200812/t20081216-2814.html,2008-07-10/2015-04-03.

引证文献11

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部